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Type 2 diabetes mellitus is a chronic illness with a rela-
tively high prevalence, and glycemic control has been funda-
mental for the management of the disease. Hemoglobin glyca-
tion was first used 30 years ago to assess glycemia in subjects 
with type 2 diabetes mellitus. Since then, the hemoglobin A1c 
(HbA1c) assay has been the standard laboratory marker of glu-
cose control and correlates well with long-term diabetes compli-
cations.1,2 Hemoglobin A1c is now a commonly used laboratory 
test for monitoring glycemia and managing type 2 diabetes 
mellitus.3 However, there is compelling evidence that the test is 
used inappropriately in clinical practice.4 
There is a growing interest in HbA1c testing for a diabe-
tes diagnosis.5 The recent report by the International Expert 
Committee (IEC) on the diagnosis of type 2 diabetes mellitus6 
recommends the use of HbA1c rather than glucose as a diagnostic 
criterion of diabetes. This report involves an important increase 
in the number of HbA1c determinations.
7 The IEC concluded 
that advances in instrumentation and standardization make 
the accuracy and precision of an HbA1c assay at least as good 
as those of glucose assays. Other advantages of HbA1c, includ-
ing low pre-analytical and biological variation, values reflecting 
long-term glycemia exposure, and no need for pre-test fasting, 
support this recommendation. In July 2009, the IEC deter-
mined that an HbA1c value of 6.5% or greater should be used 
to diagnose type 2 diabetes mellitus.6 The diagnosis should be 
confirmed by repeating the HbA1c measurement on a different 
day unless clinical symptoms and glucose values >11.1 mmol/L 
(200 mg/dl) are both present. Hemoglobin A1c concentrations 
of 5.7%-6.4% indicate individuals at high risk of developing 
type 2 diabetes mellitus. Repeat HbA1c testing is not required 
for persons with results in this range.8 Clinical laboratory pro-
fessionals will have a vital role in implementing ordering proce-
dures in conjunction with clinicians. 
The objective of this study is to evaluate the HbA1c pre-
scription patterns by primary care physicians before the IEC 
guidelines and how they have changed after the guidelines  
were published. 
Materials and Methods 
A cross-sectional study was made on the number of HbA1c 
tests ordered by general practitioners from January 2002 to 
December 2009 in a health district of Alicante, Spain. This area 
holds 10 primary care centers where general practitioners can 
order tests without having to refer the patient to the main hos-
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pital (San Juan Hospital), which serves a population of 234,424 
inhabitants. The 10 different primary care centers included in 
the study used similar order forms for laboratory tests during 
the study period, until May 2009, when an electronic order-
ing system was implemented in primary care centers. All of 
these tests were usually carried out in the Clinical Laboratory 
Department of this hospital. The method used to measure 
HbA1c was the National Glycohemoglobin Standardization 
Program (NGSP)-certified method;9 cation-exchange high-
performance liquid chromatography (CE-HPLC) (HbA1c 
Program on the VARIANT II TURBO Link System, Bio-Rad 
Laboratories, Berkeley, CA), and there were no changes during 
the study period.
The study is based on an analysis of data collected from a 
laboratory information system (LIS). Hemoglobin A1c testing 
was the primary outcome. To assess the rate of inappropriate 
test orders, laboratory records of the HbA1c tests ordered be-
tween January 2002 and December 2009 were evaluated. After 
consulting the literature regarding HbA1c values that were un-
likely to have diabetic patients,6 a <6% HbA1c result was de-
cided. Prior to the July 2009 guidelines and HbA1c testing only 
for diabetic patient management, the possible inappropriate 
HbA1c request was considered as any order for a given patient 
with an HbA1c value result of <6%. 
We examined HbA1c test-ordering activity at 10 primary 
care centers to ascertain variations in ordering practice. 
As defined above, a possible inappropriate HbA1c request 
was considered as any order for a given patient with an HbA1c 
result of <6%. Two suitability indicators were calculated for 
HbA1c orders: 1) percentage of HbA1c with a result of <6% and 
<5.5% regarding the total HbA1c requested; and 2) the number 
of repeat HbA1c determinations ordered per patient with a result 
of <6% and the number of repeat orders per patients with a 
result of >6.5% in 2008 and 2009. The first parameters, HbA1c 
with a result of <6 % and <5.5%, were used to ascertain inappro-
priate HbA1c due to probable use in nondiabetic patients and the 
second, the number of repeat HbA1c determinations ordered per 
patient with a result of <6% and >6.5%, were used to estimate 
compliance with recommendations for use in type 2 diabetic pa-
tients (ie, inappropriate use of the test due to the non-repetition 
of the test in type 2 diabetic patients in a 1-year period).
We collected the total HbA1c orders and the percentage 
of HbA1c results <6% and <5.5% regarding the total number 
of HbA1c ordered for patients managed by general practitio-
ners in each primary care center for every annual period. The 
same results were assessed from January 2009 to July 2009 
(before the IEC recommendations) and from August 2009 to 
December 2009 (after the new diagnostic HbA1c indication was 
implemented), and in the same periods in the remaining years 
of the study. The number of HbA1c tests per patient every year 
was also collected to confirm recommendations for type 2 dia-
betes mellitus control were being followed. We calculated the 
percentage of HbA1c orders with respect to the total number of 
primary care orders in these periods to highlight the increase in 
HbA1c orders with respect to total orders.
Differences in HbA1c testing between periods and between 
the 10 primary care centers were tested with the Chi-square test 
using SPSS software (Chicago, IL).
Results
A total of 95,321 HbA1c tests (patients more than 18 years 
old, 50,520 women and 44,801 men) were ordered by general 
practitioners during the study period (January 2002-December 
2009). The annual percentage of HbA1c orders regarding the 
total orders is shown in Figure 1. If we focus only on 2009, the 
percentage increases significantly in the second half of the year. 
This percentage is 18.97% for February 2009 to April 2009, 
20% for May 2009 to July 2009, and 22.51% for August 2009 
to October 2009. The differences between the first and third 
period and between the second and third period were signifi-
cant (P<0.001 and P=0.003, respectively).
The percentage of HbA1c with results of <6% and <5.5% 
regarding the total HbA1c requested by general practitioners 
were 34,548 (36.2%) and 13,163 (13.8%). The same results 
are broken down annually in Figure 2. In the January 2002 
to July 2009 and August 2009 to December 2009 periods, an 
HbA1c result <6% was found in 35.71% and 42.15%, respec-
tively. The percentage of HbA1c with a result of <6% for the 
periods January to July and August to December in the dif-
ferent years of the study are shown in Table 1. Only in 2009 
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Figure 1_Percentage of HbA1c requested from primary care centers to 
total requests. The figure shows the percentage of HbA1c requested 
from primary care centers to total requests in the study period.
Figure 2_Percentage of HbA1c tests with the results of <6% and <5.5% for 
total requested HbA1c ordered by general practitioners of Alicante every 
year during the study period. In 2009, the downward trend is reversed.
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was the difference between the 2 periods statistically significant 
(P<0.001). 
The percentage of HbA1c tests with results of <6% and 
<5.5% regarding the total HbA1c requested annually by each 
primary care center is shown in Table 2. The annual differ-
ences between each center when compared with the mean 
group were statistically significant, as were the differences 
within the same center in 2008 and 2009 (P<0.001). In 2004 
the dispersion between centers is greater in both HbA1c <6% 
in <5.5%. 
The number of HbA1c tests with a result of <6% and 
>6.5% regarding the total HbA1c ordered per patient in pri-
mary care centers in 2008 and 2009 is shown in Table 3. In a 
large number of patients, the HbA1c test was ordered only once, 
including patients with HbA1c <6% and patients with HbA1c 
>6.5%. The difference between patients with HbA1c <6% and 
patients with HbA1c >6.5% who had only 1 HbA1c test/year 
was significant (P<0.001). The percentage was lower in patients 
with diabetes (HbA1c >6.5%). However, the percentage remains 
too high (76.56%) in 2009. 
The prevalence of type 2 diabetes mellitus in the 
Autonomous Community of Valencia among subjects older 
than 18 years is 13.3%, of which 7.05% is known diabetes mel-
litus and 6.25% is unknown diabetes mellitus.10 Consequently, 
our health district should have about 13,852 patients with 
diabetes. The ADA recommends measuring HbA1c every 6 
months in patients with stable and well-controlled diabetes 
mellitus. Assuming all patients with diabetes mellitus comply 
with therapeutic objectives, about 27,704 HbA1c measurements 
should be made every year (according to data from the 2009 
census); in reality, 18,665 samples were analyzed.
Discussion
The diagnostic criteria for type 2 diabetes mellitus were 
recently modified due to standardization of the HbA1c determi-
nation method and the correlation of test results with the risk 
Table 1_Annual Comparison Between the Percentage 
of HbA1c With Results Below 6% Regarding HbA1c  
Total Orders in January to July and August to 
December Periods
 % HbA1c <6%
Year Jan-Jul Aug-Dec P Value
2002 43.61% 43.58% 0.97
2003 44.94% 43.76% 0326
2004 33.34% 33.29% 0.96
2005 37.19% 36.34% 0.37
2006 39.93% 40.81% 0.41
2007 36.37% 36.35% 0.98
2008 26.48% 26.75% 0.71
2009 38.59% 42.15% <0.001
Table 2_Percentage of HbA1c Tests With a Result of <6% and <5.5% Ordered at Different Primary Care Centers  
in Each Year of the Study
A %HbA1c <6%
Center 2002 2003 2004 2005 2006 2007 2008 2009
 1 42.91 29.21 24.60 24.65 34.44 30.73 23.91 32.73
 2 34.23 26.47 22.83 28.96 36.86 45.41 45.64 42.92
 3 46.36 41.40 41.10 37.53 29.87 26.56 24.24 39.30
 4 24.05 19.67 14.33 14.20 20.81 19.35 15.19 37.79
 5 39.02 20,37 13.67 33.43 45.89 19.05 13.04 30.60
 6 45.16 50.67 34.16 37.20 41.03 37.23 33.70 43.02
 7 38.08 24.16 19.01 39.51 40.86 38.04 20.00 40.46
 8 37.64 30.47 30.25 44.42 39.00 36.36 24.59 36.69
 9 63.00 55.60 48.99 40.45 34.96 31.61 21.89 38.76
 10 45.74 50.85 38. 22 36.76 41.43 44.02 38.65 42.46
Annual mean 41.62 34.89 28.72 33.71 36.52 32.84 26.09 38.47
SD 10.05 13.56 11.86 8.91 7.11 9.18 10.29 4.21
CV (%) 24.15 38.87 41.30 26.44 19.47 27.97 39.43 10.95
B %HbA1c <5.5%
Center 2002 2003 2004 2005 2006 2007 2008 2009
 1 27.68 13.01 7.93 8.79 12.26 9.08 4.41 9.22
 2 16.63 13.24 6.74 8.96 11.96 15.46 7.67 13.46
 3 32.77 23.84 17.04 13.89 9.41 7.18 5.76 11.74
 4 11.73 8.85 3.86 4.35 6.36 4.99 2.85 10.64
 5 25.25 10.19 3.91 14.33 19.07 7.14 2.61 10.85
 6 30.66 27.82 13.67 15.02 12.66 11.73 8.06 13.19
 7 19.49 10.6 5.1 12.59 13.65 13.94 5.17 12.45
 8 21.88 11.96 8.25 15.23 11.00 9.54 5.71 10.27
 9 53.75 33.52 20.92 14.35 10.77 10.89 4.63 10358
 10 34.43 31.88 16.73 15.31 15.54 20.04 10.01 13.54
Annual mean 27.43 18.49 10.42 12.28 12.27 11.00 5.69 11.59
SD 11.75 9.69 6.17 3.69 3.43 4.50 2.33 1.51
CV 42.84 52.41 59.24 30.06 27.98 40.91 40.93 13.00
Table 2 shows the annual percentage of HbA1c with a result lower than 6% and with a result lower than 5.5% in regards to the total HbA1c tests in each center studied. The annual differences 
between centers (each 1 with the mean for the group) were statistically significant, as were the differences within the same center in 2008 and 2009 (P<0.001).
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of developing diabetic complications.6 The cutoff point for the 
diagnosis of diabetes mellitus is set at ≥6.5%, and a group of sub-
jects at a high risk of developing diabetes mellitus is defined as 
those with HbA1c results in the 5.7%-6.4% interval. The inter-
est of this risk group is due to the observation that patients with 
HbA1c within the 5.5%-6% range have an increased risk of de-
veloping diabetes mellitus in the upcoming years.11,12 As the new 
diagnostic criteria can be expected to have an impact on the clin-
ical analysis laboratory, we decided it would be useful to analyze 
the current situation at each work center in order to manage the 
workload and anticipate any increases the new recommendations 
by the American Diabetes Association (ADA) may generate.
Our study revealed an annual increase in the demand for 
HbA1c tests in primary care. This was supported by a 3-fold 
increase in the number of HbA1c tests processed from 2002 to 
2009. This phenomenon has also been observed by other in-
vestigators, who also have reported that HbA1c tests were often 
ordered for people who did not have diabetes13,14 in the period 
before the new indications for the test were published.
It is interesting to note that not only did the number of 
HbA1c test orders increase in our study, but there was also 
a larger number of patients with <6% and even <5.5% in a 
period in which diagnostic recommendations regarding the 
use of HbA1c had not been clearly formulated. The bulk of 
the workload related to diabetic patient care weighs heavily 
on primary care physicians. The findings of our study suggest 
either an excellent control of diabetes mellitus in primary care 
or inappropriate orders for patients who do not have diabetes. 
The percentage of people with HbA1c <6% and <5.5% differed 
between primary care centers in our work area. This indicates 
differences existed in the pattern of HbA1c orders, since the 
prevalence of diabetes mellitus is similar at all the centers. 
The increase in the number of HbA1c tests ordered by 
primary care physicians since July 2009 and the increase in 
the percentages of these with results lower than 6% or 5.5% 
could be attributed to the new indication for HbA1c tests in 
the diagnosis of diabetes, although this indication was not 
formulated in ADA recommendations until January 2010.8 In 
order to clarify this point, we compared the number of HbA1c 
results below 6% and 5.5% regarding total ordered HbA1c in 
the period from August 1, 2009, until the end of 2009 with 
the January 2009 to July 2009 period. A significant difference 
was found between these 2 periods. This finding indicates that 
there were a larger number of test orders for patients who did 
not have diabetes. This increase was associated with the imple-
mentation of an electronic order system in primary care centers 
(May 2009). The short time available for patient visits and the 
complexity of the electronic laboratory order model predisposed 
physicians to choose profiles not specific for diabetes. This 
increase could also be explained by the implementation of a 
diabetes profile among the other profiles. The diabetes profile 
includes HbA1c and may be used for subjects without diabetes, 
thus aggravating the problem of inappropriate HbA1c orders. 
It has been demonstrated that the most frequent error when 
ordering laboratory tests is to add unnecessary tests.15 However, 
direct electronic orders may be a cost-effective practice for ad-
justing demand, particularly if general practitioners are properly 
trained and suitable decision-making protocols are used.16 In 
recent years, in addition to reporting an increase in the number 
of HbA1c tests ordered for patients who do not have diabetes, 
there has also been an inappropriate use of HbA1c noncompli-
ant with test-ordering guidelines for optimal diabetes control.17 
One limitation of our study is that we could not establish the 
diagnosis of diabetes mellitus in patients in which HbA1c was 
determined because we did not have this information in the 
laboratory database. What is clear, however, is that patients 
with HbA1c >6.5% are diabetic. For that reason, we can assess 
the adequacy of the HbA1c test in this group by evaluating the 
number of times in a year the test was performed and its rela-
tion to the number of individuals with diabetes in our popula-
tion. In view of the number of times per year the HbA1c test is 
repeated, it is clear that a large percentage of these patients have 
the test only once a year. This finding reflects the scant num-
ber of HbA1c tests ordered for the diabetes mellitus follow-up. 
This finding is even more serious if we subtract the percentage 
of patients who probably do not have diabetes (HbA1c <6%) 
from the total number of HbA1c tests ordered by primary care. 
One caveat to this last statement might be that a large number 
of patients with diabetes could be within therapeutic range. 
However, it has been reported that the percentage of patients 
with type 2 diabetes and HbA1c ≤6.5% is in the range of 18%-
28%. Consequently, considering the small number of annual 
HbA1c determinations, much lower than recommended, the 
majority of determinations with a result of <6% most likely 
correspond to persons without diabetes.18 In any case, another 
working group, using data from a single primary care center in 
which diabetes mellitus management guides are applied, has 
been able to achieve HbA1c <7% in 54.8% of patients.
19 
Therefore, one noteworthy problem disclosed is the inap-
propriate use of HbA1c tests given the small number performed 
on patients with diabetes mellitus and the likelihood of overuse 
in patients who do not have diabetes. 
Table 3_Number of HbA1c Tests With a Result of <6% and >6.5% Carried Out Per Person in 2008 and 2009
 2008    2009
 Patients With HbA1c <6% Patients With HbA1c >6.5% Patients With HbA1c <6% Patients With HbA1c >6.5%
All patients 4697 5873  8035 4924
1 HbA1c per patient 4543 (96.72%)              5273 (89.78%) 7408 (92.20%) 3770 (76.56%)
2 HbA1c per patient 148 (3.15%)          553 (9.42%) 576 (7.17%) 958 (19.46%)
3 HbA1c per patient 6 (0.13%)        43 (0.73%) 51 (0.63%) 170 (3.45%)
4 HbA1c per patient 0      4 (0.07%) 0  20 (0.41%)
5 HbA1c per patient 0 0  0  5 (0.10%)
6 HbA1c per patient 0 0  0 1 (0.02%)
The difference between patients with HbA1c <6% and patients with HbA1c >6.5% in which only 1 HbA1c test ordered was significant ( P<0.001). Although the percentage HbA1c requested once  
is lower in patients with HbA1c >6.5%, it is too high.
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New diagnostic criteria of diabetes mellitus will change 
HbA1c test habits of primary care physicians. Moreover, the in-
dications for HbA1c testing and test periodicity should be made 
more clear. At the present time, screening for diabetes mellitus 
is advised in everyone over age 45, whether or not they have 
risk factors for the development of diabetes. If the test result 
is normal, the test should be repeated every 3 years. The age 
for screening is younger in adults with diabetes risk factors.20 
Patients with HbA1c results between 5.7% and 6.4% should be 
tested more frequently.
Two determinations of HbA1c every year are recom-
mended for diabetic patients with good glucose control. 
However, an HbA1c determination every 3 months is recom-
mended for diabetic patients with poor glucose control or when 
significant changes in the therapeutic scheme are made.
If a first HbA1c determination is normal, it should be 
repeated in 3 years, because of progressive risk of developing 
diabetes with age.21 
Conclusion
This study has shown it is necessary to conduct studies of 
HbA1c testing patterns in health districts in order to collect and 
analyze data and establish corrective measures to ensure proper 
use of the tests. The key to achieving this goal is interdepart-
mental cooperation between endocrinologists and primary care 
and laboratory professionals to develop protocols and guidelines 
and put them into practice. It is also necessary to evaluate test-
ordering patterns by examining indicators of the appropriate-
ness of demand in order to adhere to guidelines for ordering the 
test and to correct possible deviations. Such studies are crucial, 
particularly given the current imperious need to optimize  
efficiency in medicine.  LM
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